Is stereotactic body radiotherapy (SBRT) to the prostate bed indicated for a patient with oligometastatic prostate cancer after definitive surgery, limited metastatic sites (≤3–5), rising PSA, and ECOG performance status 0‑1?

SBRT to Prostate Bed in Oligometastatic Prostate Cancer

SBRT to the prostate bed in oligometastatic prostate cancer after radical prostatectomy is a reasonable treatment option, but the evidence supporting its benefit remains uncertain and should be carefully weighed against the established benefits of systemic therapy intensification. 1

Guideline Recommendation

The 2024 AUA/ASTRO/SUO guidelines provide a conditional recommendation (Grade C evidence) that clinicians may perform SABR/SBRT metastasis-directed therapy (MDT) in patients with oligorecurrent disease following primary salvage therapy, but must carefully consider toxicity versus uncertain benefits. 1

The Critical Clinical Dilemma

The incorporation of advanced imaging (PSMA-PET) has fundamentally changed this landscape, creating a clinical conundrum:

• Historically, patients with biochemical recurrence after radical prostatectomy and negative conventional imaging received salvage radiotherapy to the prostate bed as standard of care
• Now, with PSMA-PET detecting oligometastases earlier, it remains unknown whether salvage RT to the prostate bed provides benefit when metastatic disease is already visible 1

Two Competing Paradigms:

1. Omit prostate bed RT: Patients with visible metastatic disease are unlikely curable with local therapy alone; focus on systemic therapy
2. Oligometastatic paradigm: Treat both prostate bed AND metastatic sites with SBRT as part of comprehensive MDT 1

Currently, no comparative data exist to guide this decision. 1

Evidence Supporting MDT (to Metastases, Not Specifically Prostate Bed)

The strongest evidence for SBRT in oligometastatic prostate cancer comes from treating the metastatic sites themselves, not the prostate bed:

Key Randomized Trials:

STOMP Trial (n=62): MDT (surgery or RT to metastases) improved ADT-free survival versus observation (21 vs 13 months; HR 0.60), with no grade ≥2 toxicity and preserved quality of life. 1

ORIOLE Trial (n=54): SBRT to metastases improved median PFS (not reached vs 5.8 months; HR 0.30) with good tolerability. 1, 2

Combined analysis of STOMP and ORIOLE showed pooled HR of 0.44 for PFS with MDT (median follow-up 52.5 months). 2

Important Limitations:

• These trials focused on treating metastatic sites, not the prostate bed
• Primary endpoint was delaying ADT initiation, not overall survival
• Small phase II trials only
• The benefit of adding prostate bed RT to metastasis-directed therapy remains unproven

Toxicity Profile

SBRT appears safe in the post-prostatectomy setting:

• POPSTAR trial: 14% grade 2,3% grade 3 toxicity; >90% local control at 2 years 1
• Prospective phase II data: No grade ≥3 toxicity, 12.2% late grade 2 GU toxicity (primarily incontinence), preserved quality of life 3

The Systemic Therapy Consideration

Critical caveat: Standard treatment for metastatic prostate cancer now includes intensified systemic therapy (ADT + androgen receptor pathway inhibitors ± chemotherapy) based on high-quality evidence. 1

The guidelines emphasize that applying systemic therapy data from conventional imaging-positive patients to PET-only detected disease risks overtreatment, but the converse—relying solely on local therapy—may represent undertreatment. 1

Practical Algorithm for Decision-Making

When SBRT to Prostate Bed + Metastases May Be Reasonable:

• ≤3-5 metastatic sites on conventional imaging (or ≤10 on PSMA-PET per evolving definitions) 2
• Good performance status (ECOG 0-1)
• Patient preference to delay systemic therapy
• All sites (including prostate bed) technically amenable to SBRT
• Must treat ALL sites including metastases—not prostate bed alone

When to Prioritize Systemic Therapy Over/With Local Therapy:

• Higher metastatic burden
• Rapid PSA doubling time
• High-risk pathologic features suggesting aggressive biology
• Symptomatic disease
• Patient preference for definitive systemic control

The Shared Decision-Making Discussion Must Include:

1. Uncertain benefit: No proven overall survival advantage for prostate bed RT in oligometastatic setting
2. Toxicity trade-offs: SBRT has modest toxicity (12% late grade 2 GU) but delays systemic therapy with proven survival benefits
3. Treatment sequencing: MDT may delay but not replace eventual need for systemic therapy
4. Imaging sensitivity: PSMA-PET may reveal additional sites during treatment planning

Common Pitfalls to Avoid

• Do not treat prostate bed alone while ignoring visible metastases—this contradicts the oligometastatic paradigm
• Do not assume curability—MDT delays progression but doesn't replace systemic therapy in truly metastatic disease
• Do not apply conventional imaging-negative salvage RT data to PET-positive oligometastatic patients—these are different clinical scenarios 1
• Do not delay systemic therapy indefinitely in patients with aggressive features who would clearly benefit from ADT intensification

Bottom Line

For your specific patient (oligometastatic after surgery, ≤3-5 sites, rising PSA, ECOG 0-1): SBRT to both the prostate bed AND all metastatic sites is a reasonable approach within an oligometastatic treatment paradigm, but acknowledge this represents extrapolation from limited evidence. The alternative—systemic therapy with ADT + ARPI—has stronger evidence for survival benefit in metastatic disease. The optimal approach likely involves both MDT to all sites (including prostate bed) AND consideration of systemic therapy, particularly if high-risk features are present. 1, 2

The 2025 NCCN guidelines support MDT for oligometastatic CSPC, noting the goal is to treat all metastatic sites, which may include the primary tumor/prostate bed if untreated or recurrent. 2